But experts warn that the drug is not a cure. Dr. Joy Snider is a brain doctor at Washington University in St. Louis, Missouri. She said, “This drug is not a cure. It doesn’t stop people from getting worse, but it does measurably slow the progression of the disease.” She added, “That might mean someone could have an extra six months to a year of being able to drive.”
Like other amyloid-targeting medications, Leqembi can cause brain swelling or small brain bleeds. Patients also may experience reactions from the drug that could include high body temperature, an upset stomach and changes in blood pressure.
The drug is designed to target and clear away beta-amyloid, a substance that builds up in the brain and leads to Alzheimer’s disease.
In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months.
دیدگاهها (0)